| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22b9baa71ceef111b94d9fcf4391f1f0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 |
| filingDate |
2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88d542c2d282c42bd4674c9e85ca0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_800432b04aecbc9dc7b3172db5676f2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74d2aa7a4c7e61fc033091b5138a9f4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baf3e667d4ebec1c76b44859a00abc49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d02d95393a5e917b1276af6d2765f001 |
| publicationDate |
2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3026900-A1 |
| titleOfInvention |
Radio-pharmaceutical complexes |
| abstract |
The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising admistration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided. |
| priorityDate |
2016-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |